… suggested a kinase inhibitor combination therapy that produced … We used RNAi for each
kinase in the MAPK pathway to … coincides with the reactivation of RAF-MEK-ERK signaling. …

… involves reactivation of the MAPK (RAF/MEK/ERK) pathway … that are sensitive to MAP kinase
pathway inhibitors. These cells … MEK inhibitor trametinib (GSK1120212), or the combination …

… or BRAFV600E-MEK MUT , which lead to MAPK pathway reactivation. Cells with
combination-drug … We recently described both MAPK pathway reactivation and PI3K pathway …

… shown to result in either reactivation of the ERK1/2 signaling, failure to effectively deactivate
ERK1/2, or activate alternative signaling pathways that overcome the inhibition of ERK1/2. …

… Screening of a MAPKi library revealed MEK inhibitors as the class inhibiting the pathway
with the lowest IC 50 s, followed by ERK and next-generation RAF inhibitors. Combination …

… RTK-mediated reactivation of the MAPK pathway … , combined inhibition of BRAF, EGFR, and
MEK is hypothesized to prevent adaptive feedback reactivation and maintain MAPK pathway …

… In conclusion, we demonstrate that combining sorafenib and … suggests that this combination
warrants further investigation … of multiple pathways by the two-drug combination contributes …

… in tumor microenvironment could reactivate the MAPK/ERK and PI3K/AKT pathways.
Resistance is also acquired through reactivation of the MAPK/ERK pathway, which can happen …

… melanoma to date result in reactivation of MEK/ERK signaling (5–11). … combined targeting
of BRAF and MEK. In a phase I/II trial of combined dabrafenib and tremetinib, this combination …

… The effect of MAPK signaling inhibition is compatible with stable disease, and thus again,
reactivation of the PI3K signaling might limit the single agent activity of MEK inhibition. …